Abstract | INTRODUCTION: CASE REPORT: A 53-year-old male presented an absolute eosinophil count of 25,000/mm(3), anemia (Hb 10.2 g/dl) and a moderate increase in the platelet count (571,000/mm(3)). A clinical examination revealed left exophthalm, associated with diffuse hypoesthesia and diplopia. A CT scan of orbits showed a lesion located in the lachrymal fossa of the left orbit with intra- and extra-conical extension. Molecular analysis excluded the presence of bcr/abl transcript while a F/P fusion tyrosine kinase signal was documented. Imatinib mesylate (IM) was started and, after 7 days of treatment eosinophil count significantly declined along with a dramatic reduction of the left exophthalm. IM dosage was increased up to 300 mg/day. The drug was well tolerated with an initial modest haematological toxicity. The left exophthalm, as well as hypoesthesia and diplopia, disappeared after IM therapy. MRI showed a clear reduction of the intra- and extra-conical growth process. BM molecular signal of the F/P fusion gene resulted undetectable after 4 weeks of treatment. CONCLUSION: In our case, the diagnosis of FIPIL1-PDGFRA-positive CEL and IM therapy has allowed the patient to experience an excellent clinical therapeutic result, avoiding surgical treatment of the retro-orbital mass.
|
Authors | Ernesto Vigna, Eugenio Lucia, Massimo Gentile, Carla Mazzone, Maria Grazia Bisconte, Carlo Gentile, Antonio Armentano, Emanuela Ottaviani, Michela Rondoni, Giovanni Martinelli, Fortunato Morabito |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 61
Issue 4
Pg. 713-6
(Apr 2008)
ISSN: 0344-5704 [Print] Germany |
PMID | 17549478
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Oncogene Proteins, Fusion
- Piperazines
- Pyrimidines
- mRNA Cleavage and Polyadenylation Factors
- Imatinib Mesylate
- FIP1L1-PDGFRA fusion protein, human
- Receptor, Platelet-Derived Growth Factor alpha
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Benzamides
- Humans
- Hypereosinophilic Syndrome
(drug therapy, genetics)
- Imatinib Mesylate
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Oncogene Proteins, Fusion
(metabolism)
- Orbital Neoplasms
(drug therapy, genetics)
- Piperazines
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Receptor, Platelet-Derived Growth Factor alpha
(metabolism)
- Reverse Transcriptase Polymerase Chain Reaction
- Tomography, X-Ray Computed
- mRNA Cleavage and Polyadenylation Factors
(metabolism)
|